(PHR) Phreesia - Ratings and Ratios
Patient Check-in Software,Payment Processing,Revenue Cycle Services
PHR EPS (Earnings per Share)
PHR Revenue
Description: PHR Phreesia August 13, 2025
Phreesia Inc, listed on the NYSE under the ticker symbol PHR, operates within the Health Care Technology sub-industry. The companys quarterly tax provision data is a critical component of its financial health, influencing its overall profitability and cash flow.
To understand Phreesias financial standing, key performance indicators (KPIs) such as revenue growth, operating margins, and cash flow generation are essential. The companys ability to manage its tax provision effectively can significantly impact these KPIs, ultimately affecting its valuation and investor attractiveness.
The healthcare technology sector, in which Phreesia operates, is driven by factors such as the adoption of digital health technologies, regulatory changes, and the need for cost containment in healthcare systems. Phreesias business model, which likely revolves around providing technology solutions to healthcare providers, is influenced by these broader industry trends.
With a market capitalization of $1.607 billion, Phreesias size and scale suggest a considerable presence in the healthcare technology space. The companys forward Price-to-Earnings (P/E) ratio of 90.91 indicates that investors have high growth expectations, which could be tied to the companys ability to expand its customer base, enhance its product offerings, or improve operational efficiency.
The negative Return on Equity (RoE) of -16.23% is a concern, suggesting that Phreesia is currently not generating profits for its shareholders. This could be due to various factors, including investment in growth initiatives, operational challenges, or market conditions. Investors will be keenly watching the companys ability to turn this around.
Key economic drivers for Phreesia include the overall growth of the healthcare technology market, the companys competitive positioning within this market, and its ability to innovate and adapt to changing regulatory and market conditions. The companys financial health, as reflected in its tax provision and other financial metrics, will be critical in determining its ability to capitalize on these drivers.
PHR Stock Overview
| Market Cap in USD | 1,374m |
| Sub-Industry | Health Care Technology |
| IPO / Inception | 2019-07-18 |
PHR Stock Ratings
| Growth Rating | -6.96% |
| Fundamental | 57.1% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 9.31% |
| Analyst Rating | 4.67 of 5 |
PHR Dividends
Currently no dividends paidPHR Growth Ratios
| Growth Correlation 3m | -78% |
| Growth Correlation 12m | 22.5% |
| Growth Correlation 5y | -64.1% |
| CAGR 5y | -5.69% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.08 |
| CAGR/Mean DD 3y (Pain Ratio) | -0.17 |
| Sharpe Ratio 12m | 0.46 |
| Alpha | 6.61 |
| Beta | 0.684 |
| Volatility | 49.95% |
| Current Volume | 302.8k |
| Average Volume 20d | 583.9k |
| Stop Loss | 22.4 (-4.6%) |
| Signal | -0.06 |
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income (-24.1m TTM) > 0 and > 6% of Revenue (6% = 27.0m TTM) |
| FCFTA 0.09 (>2.0%) and ΔFCFTA 15.43pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 26.13% (prev 20.24%; Δ 5.89pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.13 (>3.0%) and CFO 51.7m > Net Income -24.1m (YES >=105%, WARN >=100%) |
| Net Debt (-93.5m) to EBITDA (6.85m) ratio: -13.66 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.12 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (59.3m) change vs 12m ago 3.06% (target <= -2.0% for YES) |
| Gross Margin 72.52% (prev 60.93%; Δ 11.59pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 116.7% (prev 107.7%; Δ 9.01pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -10.44 (EBITDA TTM 6.85m / Interest Expense TTM 2.06m) >= 6 (WARN >= 3) |
Altman Z'' -12.54
| (A) 0.29 = (Total Current Assets 222.6m - Total Current Liabilities 105.1m) / Total Assets 408.6m |
| (B) -1.97 = Retained Earnings (Balance) -804.8m / Total Assets 408.6m |
| warn (B) unusual magnitude: -1.97 — check mapping/units |
| (C) -0.06 = EBIT TTM -21.5m / Avg Total Assets 385.4m |
| (D) -7.27 = Book Value of Equity -804.0m / Total Liabilities 110.6m |
| Total Rating: -12.54 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 57.12
| 1. Piotroski 6.0pt = 1.0 |
| 2. FCF Yield 2.73% = 1.36 |
| 3. FCF Margin 7.76% = 1.94 |
| 4. Debt/Equity 0.02 = 2.50 |
| 5. Debt/Ebitda -13.66 = 2.50 |
| 6. ROIC - WACC (= -18.97)% = -12.50 |
| 7. RoE -8.75% = -1.46 |
| 8. Rev. Trend 99.00% = 7.42 |
| 9. EPS Trend 86.95% = 4.35 |
What is the price of PHR shares?
Over the past week, the price has changed by +5.34%, over one month by -0.76%, over three months by -13.20% and over the past year by +29.37%.
Is Phreesia a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of PHR is around 20.72 USD . This means that PHR is currently overvalued and has a potential downside of -11.75%.
Is PHR a buy, sell or hold?
- Strong Buy: 10
- Buy: 5
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the PHR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 33.8 | 44% |
| Analysts Target Price | 33.8 | 44% |
| ValueRay Target Price | 23.1 | -1.6% |
PHR Fundamental Data Overview October 17, 2025
P/E Forward = 384.6154
P/S = 3.0552
P/B = 4.5923
Beta = 0.684
Revenue TTM = 449.7m USD
EBIT TTM = -21.5m USD
EBITDA TTM = 6.85m USD
Long Term Debt = 4.58m USD (from longTermDebt, last quarter)
Short Term Debt = 7.10m USD (from shortLongTermDebt, last quarter)
Debt = 4.75m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -93.5m USD (from netDebt column, last quarter)
Enterprise Value = 1.28b USD (1.37b + Debt 4.75m - CCE 98.3m)
Interest Coverage Ratio = -10.44 (Ebit TTM -21.5m / Interest Expense TTM 2.06m)
FCF Yield = 2.73% (FCF TTM 34.9m / Enterprise Value 1.28b)
FCF Margin = 7.76% (FCF TTM 34.9m / Revenue TTM 449.7m)
Net Margin = -5.35% (Net Income TTM -24.1m / Revenue TTM 449.7m)
Gross Margin = 72.52% ((Revenue TTM 449.7m - Cost of Revenue TTM 123.6m) / Revenue TTM)
Gross Margin QoQ = 85.16% (prev 67.17%)
Tobins Q-Ratio = 3.13 (Enterprise Value 1.28b / Total Assets 408.6m)
Interest Expense / Debt = 9.15% (Interest Expense 435.0k / Debt 4.75m)
Taxrate = -100.0% (out of range, set to none) (563.0k / -563.0k)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 2.12 (Total Current Assets 222.6m / Total Current Liabilities 105.1m)
Debt / Equity = 0.02 (Debt 4.75m / totalStockholderEquity, last quarter 298.0m)
Debt / EBITDA = -13.66 (Net Debt -93.5m / EBITDA 6.85m)
Debt / FCF = -2.68 (Net Debt -93.5m / FCF TTM 34.9m)
Total Stockholder Equity = 274.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -5.89% (Net Income -24.1m / Total Assets 408.6m)
RoE = -8.75% (Net Income TTM -24.1m / Total Stockholder Equity 274.9m)
RoCE = -7.68% (EBIT -21.5m / Capital Employed (Equity 274.9m + L.T.Debt 4.58m))
RoIC = -10.46% (negative operating profit) (EBIT -21.5m / (Assets 408.6m - Curr.Liab 105.1m - Cash 98.3m))
WACC = 8.51% (E(1.37b)/V(1.38b) * Re(8.54%) + (debt cost/tax rate unavailable))
Discount Rate = 8.54% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 3.57%
[DCF Debug] Terminal Value 68.24% ; FCFE base≈34.9m ; Y1≈22.9m ; Y5≈10.5m
Fair Price DCF = 3.16 (DCF Value 189.5m / Shares Outstanding 59.9m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 86.95 | EPS CAGR: 188.9% | SUE: 0.34 | # QB: 0
Revenue Correlation: 99.00 | Revenue CAGR: 18.75% | SUE: 0.37 | # QB: 0
Additional Sources for PHR Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle